Literature DB >> 26382898

International Outcomes of the Boston Type I Keratoprosthesis in Stevens-Johnson Syndrome.

Jamie K Alexander1, Samar K Basak, Ma Dominga B Padilla, Fei Yu, Anthony J Aldave.   

Abstract

PURPOSE: To determine the factors influencing outcomes of Boston type I keratoprosthesis implantation in Stevens-Johnson syndrome (SJS) and to compare the results with those of individuals without SJS.
METHODS: This is a multicenter, retrospective, comparative consecutive case series of patients undergoing keratoprosthesis implantation in Los Angeles, Kolkata, and Manila. Statistical analysis was performed to identify significant differences in visual acuity, complications, and retention between SJS and non-SJS populations.
RESULTS: A total of 234 keratoprosthesis procedures were performed in 209 eyes, including 40 performed in 27 eyes of 26 patients with SJS. Procedures in patients with SJS were more frequently performed as repeat keratoprostheses (33% vs. 8%, P < 0.001) but less frequently in eyes with glaucoma (26% vs. 71%, P < 0.001) or multiple previous keratoplasties (15% vs. 59%, P < 0.001). A significantly greater percentage of individuals with SJS had a corrected distance visual acuity ≥20/200 12 months after surgery compared with individuals without SJS (100% vs. 67%, P = 0.002). Several postoperative complications were more common in SJS, including corneal stromal necrosis (59% vs. 8%, P < 0.001), corneal infiltrates (30% vs. 10%, P = 0.009), and persistent corneal epithelial defects (59% vs. 24% P < 0.001), which led to a higher retention failure rate (0.306/eye-year vs. 0.068/eye-year, P < 0.001) and secondary surgical procedures. However, after repeat implantation, eyes with SJS were no less likely to ultimately retain a keratoprosthesis (82% vs. 89%, P = 0.34).
CONCLUSIONS: The Boston type I keratoprosthesis is an effective means to restore vision in individuals with SJS. Although retention failure and several postoperative complications are more common in SJS, sight-threatening complications such as endophthalmitis and retinal detachment are not.

Entities:  

Mesh:

Year:  2015        PMID: 26382898     DOI: 10.1097/ICO.0000000000000619

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  A cross-sectional comparative study on chronic ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series.

Authors:  Loraine L W Chow; Alex L K Ng; Sharon S W Chow; Bonnie N K Choy; Kendrick C Shih; Ian Y H Wong; Johnny C Y Chan; Jimmy S M Lai
Journal:  Int Ophthalmol       Date:  2017-05-25       Impact factor: 2.031

Review 2.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

Review 3.  The Ocular Surface and How It Can Influence the Outcomes of Keratoprosthesis.

Authors:  Sarah Moussa; Herbert Reitsamer; Josef Ruckhofer; Günther Grabner
Journal:  Curr Ophthalmol Rep       Date:  2016-11-05

4.  Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study.

Authors:  Kai B Kang; Faris I Karas; Ruju Rai; Joelle A Hallak; Joann J Kang; Jose de la Cruz; Maria S Cortina
Journal:  PLoS One       Date:  2018-02-06       Impact factor: 3.240

Review 5.  Boston Type 1 Keratoprosthesis: Updated Perspectives.

Authors:  Manachai Nonpassopon; Muanploy Niparugs; Maria Soledad Cortina
Journal:  Clin Ophthalmol       Date:  2020-04-29

6.  Corneal transplantation outcomes after the extrusion of an intrastromal keratoprosthesis: a pilot study.

Authors:  Chiara Fariselli; Ibrahim Toprak; Olena Al-Shymali; Jorge L Alio Del Barrio; Jorge L Alio
Journal:  Eye Vis (Lond)       Date:  2020-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.